This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
| Yesterday’s UK 100 Leaders | Price (p) | % Chg |
| St. James’s Place PLC | 1,210.2 | 4.5% |
| Rightmove PLC | 797.6 | 2.2% |
| Airtel Africa PLC | 198.5 | 1.8% |
| BP PLC | 404.9 | 1.8% |
| Intertek Group PLC | 4,970.4 | 1.2% |
| Yesterday’s UK 100 Laggards | Price (p) | % Chg |
| BT Group PLC | 210.4 | -5.5% |
| Babcock International Group PLC | 1,013.0 | -2.9% |
| Marks And Spencer Group PLC | 346.1 | -2.5% |
| Rio Tinto PLC | 4,580.0 | -2.1% |
| Diageo PLC | 1,935.0 | -2.1% |
| Major World Indices | Price | % Chg | 1 Year |
| UK 100 INDEX | 9,081 | -0.4% | 9.6% |
| DOW JONES INDUS. AVG | 44,767 | -0.3% | 10.7% |
| DAX INDEX | 23,970 | -1.0% | 30.2% |
| NIKKEI 225 | 40,998 | -1.1% | 6.6% |
| S&P/ASX 200 INDEX | 8,698 | 0.4% | 8.9% |
| Commodities | Units | Price | % Chg |
| WTI Crude Oil (Nymex) | USD/bbl. | 66.52 | 2.09% |
| Brent Crude (ICE) | USD/bbl. | 69.85 | 2.06% |
| Gold Spot | USD/t oz. | 3,313 | -0.7% |
| Copper (Comex) | USd/lb. | 561 | -3.0% |
Click graph to enlarge
The UK 100 called to open +12 points this morning at 9,093. The UK 100 looks set to recover some of yesterdays decline at the open, the UK’s blue-chip index dropped yesterday after initial optimism for the trade deal between the US and the EU faded.
Stateside yesterday saw the S&P end Monday near the flatline as traders looked past a trade deal announced between the U.S. and the European Union, and instead to a big week of macro announcements, including the Federal Reserve’s rate decision. The broad market index added 0.02% and closed at 6,389.77. The S&P 500 hit a fresh record shortly after the opening bell, but the index was just up 0.2% at its session high as traders’ enthusiasm for the deal with the EU was muted. The Dow Jones slipped 64.36 points, or 0.14%, to end at 44,837.56. The Nasdaq added 0.33% and settled at 21,178.58. The technology-heavy index also hit a record on Monday.
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and global trade risks remain challenges. The company hopes to move on from scandals in China, after indicating that any impact from probes in its second-biggest market would be minor, and focus on growing its U.S. footprint and drug pipeline to reach $80 billion in annual revenue by 2030.
Barclays today said half-year pre-tax profits rose 23% to £5.2 billion, boosted by a 28% improvement in the second quarter of the year. It announced a further £1 billion share buyback and a 3% higher half year dividend of 3p a share, representing a 21% increase in capital distributions to £1.4 billion for the half year. Chief executive C. S. Venkatakrishnan said: “We remain on track to achieve the objectives of our three-year plan, delivering structurally higher and more stable returns for our investors.”
Croda International reported a 7% sales growth at constant currency for the first half of 2025, driven by increased volumes across all business sectors, particularly in Beauty Care and Crop Protection. Despite a challenging environment, the company is on track with its strategic plan to enhance earnings and returns, with a focus on cost savings and operational efficiency, aiming for £100m in annualized savings by 2027.
Games Workshop reported a nearly 30% jump in annual pre-tax profit on Tuesday, boosted by sales of its flagship Warhammer 40,000: Space Marine 2 game. The firm, known for its costly and fantastical medieval fantasy-themed wargame miniatures, has been leveraging its popular Warhammer intellectual property through various licensing deals.
Greggs reported a 14% fall in first half profit, reflecting a previously flagged slowdown in sales growth in June which it blamed on very warm weather. Greggs, known for its sausage rolls, steak bakes, vegan alternatives and sweet treats, said on Tuesday it made a pretax profit of 63.5 million pounds ($84.8 million) in the six months to June 28, down from 74.1 million pounds in the same period last year, on total sales up 7.0% to 1.03 billion pounds, boosted by new store openings.
UK
AstraZeneca (AZN)
Barclays (BARC)
ConvaTec Group (CTEC)
Croda International (CRDA)
Entain (ENT)
Games Workshop (GAW)
Greggs (GRG)
Inchcape (INCH)
Morgan Sindall Group (MGNS)
Shaftesbury Capital (SHC)
US
Boeing (BA) PMO
PayPal Holdings (PYPL) PMO
Procter & Gamble (PG) PMO
Spotify Technology SA (SPOT) PMO
UnitedHealth Group (UNH) PMO
Booking Holdings (BKNG) AMC
MARA Holdings Inc (MARA) AMC
Mondelez (MDLZ) AMC
Starbucks Corp (SBUX) AMC
Teladoc (TDOC) AMC
Visa (V) AMC
UK
BAE Systems (BA.)
HSBC Holdings (HSBA)
Rathbones Group (RAT)
Rio Tinto (RIO)
Taylor Wimpey (TW.)
GSK (GSK)
US
Automatic Data Processing (ADP) PMO
Etsy (ETSY) PMO
Fiverr International (FVRR) PMO
The Kraft Heinz Co (KHC) PMO
Takeda Pharmaceutical (TAK) PMO
ARM Holdings (ARM) AMC
Ford Motor (F) AMC
Markel Group (MKL) E
Meta Platforms (META) AMC
Microsoft Corp (MSFT) AMC
Qualcomm Inc (QCOM) AMC
US Housing Price Index
US Consumer Confidence
US JOLTS Job Openings
UK 100 companies going ex-dividend on 31st July 2025:
Lloyds Banking Group
UK 250 companies going ex-dividend on 31st July 2025:
HICL Infastructure
MONY Group
Brunner Investment Trust
For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.